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Abstract. Background/Aim: Decreasing the vascularity of
a tumour has proven to be an effective strategy to suppress
tumour growth and metastasis. Anti-angiogenic therapies
have revolutionized the treatment of advanced-stage cancers,
however there is still demand for further improvement. This
necessitates new experimental models that will allow
researchers to reliably study aspects of angiogenesis. The
aim of this study was to demonstrate an in vivo technique in
which the highly vascular and accessible chorioallantoic
membrane (CAM) of the chick embryo is used to study
tumour-induced changes in the macro and microvessels.
Materials and Methods: Two cancer cell lines (human
melanoma (C8161) and human prostate cancer (PC3)) were
selected as model cells. Human dermal fibroblasts were used
as a control. One million cells were labelled with green
fluorescent protein and implanted on the CAM of the chick
embryo at embryonic development day (EDD) 7 and
angiogenesis was evaluated at EDDs 10, 12 and 14. A
fluorescently-tagged lectin (lens culinaris agglutinin (LCA))
was injected intravenously into the chick embryo to label
endothelial cells. The LCA is known to label the luminal
surface of endothelial cells, or dextrans, in the CAM
vasculature. Macrovessels were imaged by a hand-held
digital microscope and images were processed for
quantification. Microvessels were evaluated by confocal
microscopy. Tumour invasion was assessed by histological
and optical sectioning. Results: Tumour cells (C8161 and
PC3) produced quantifiable increases in the total area
covered by blood vessels, compared to fibroblasts when
assessed by digital microscopy. Tumour invasion could be
demonstrated by both histological and optical sectioning.
The most significant changes in tumour vasculature observed
were in the microvascular structures adjacent to the tumour
cells, which showed an increase in the endothelial cell
coverage. Additionally, tumour intravasation and tumour
thrombus formation could be detected in the areas adjacent
to tumour cells. The fragility of tumour blood vessels could
be demonstrated when tumour cells seeded on a synthetic
scaffold were grown on CAM. Conclusion: We report on a
modification to a well-studied CAM in vivo assay, which can
be effectively used to study tumour induced changes in
macro and microvasculature.
In 2012 8.2 million people worldwide died from cancer (1),
mainly due to a lack of complete understanding of the
biological processes leading to cancer metastasis. Tumour
growth and metastasis are dependent on angiogenesis (2).
The finding that blocking angiogenic pathways stops the
progression of cancer represents a milestone in angiogenesis
research (3). Anti-angiogenic therapies such as the anti-
VEGF antibody (Bevacuzimab) and VEGF receptor kinase
inhibitors (sunitinib and sorafenib) are now indicated in the
treatment of advanced stage cancers such as colon, lung,
breast and kidney (4, 5). However, many patients do not
show a sustained response to these agents (6). Resistance to
therapy is common and it cannot currently be predicted (7).
Additionally, some patients have less benefit from the
treatment, indicating that different cancers vascularize with
different mechanisms (8). Thus, targeting angiogenic
pathways may be an effective strategy to fight against cancer
however a better understanding of tumour vascularization
and mechanisms leading to development of resistance is
essential when developing new treatment agents (9). This
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can only be achieved by using relevant experimental models
to study tumour angiogenesis.
Traditional methods to study tumour angiogenesis rely
mainly on 2D cell cultures and small animal models. The
obvious limitation of 2D culture methods is that they fail to
recreate complex cell-cell and cell-matrix interactions in the
tumour microenvironment (10). On the other hand, the
available in vivo models are expensive, do not allow for high
throughput screening and require expertize (e.g. dorsal skin
fold assay) if visualization of blood vessels is required.
Increasingly more research is focusing on constructing 3D in
vitro models of tumour angiogenesis using tissue-engineering
techniques (11, 12). However, this field is still developing. 
The chorioallantoic membrane (CAM) assay stands out as
an economical alternative bioassay to study tumour
angiogenesis in vivo. The CAM provides researchers with a
readily accessible dense network of visible arteries and veins
that allows nutrients for efficient grafting of tumour cells.
When a fluorescently tagged lectin (lens culinaris agglutinin
(LCA)) is injected into the circulation of the chick embryo,
the capillary plexus of the CAM can be visualized by a top
planar view in the fluorescent microscope. The planar
arrangement of this capillary plexus (microvasculature) and
its proximity to the surface makes it a valuable model to
study angiogenic processes at the cellular level, in both
physiological and pathological situations. Additionally, the
chick embryo is essentially immunodeficient in the initial
stages of embryonic life, unlike murine models that do not
support the growth of all human tumour types. More
importantly, the CAM model offers distinctive advantages
when studying angiogenesis. 
Tumour angiogenesis is driven by several mechanisms
including sprouting angiogenesis, intussusceptive angiogenesis
and recruitment of endothelial progenitor cells, vessel co-
option, vasculogenic mimicry and lymphangiogenesis (13).
The first advantage of the CAM model is that it allows direct
visualization of sprouting and intussusceptive angiogenesis,
which can be of particular importance when alternative
pathways in treatment resistance are, to be studied. Secondly,
the CAM assay allows monitoring of tumour intravasation into
the CAM microvasculature (14). Intravasation is entry of
tumour cells into the vasculature and it is the most critical step
in initiation of tumour metastasis (15). Intravasation is
considered to be the rate-limiting step in cancer metastasis
however it is under- investigated (16), due to the requirement
for sophisticated technical imaging equipment (e.g. time-lapse
confocal microscopy) that is required to study in vivo tumour
intravasation and metastasis (17). 
The aim of this study is to describe a methodology that
allows evaluation and quantification of the effect of a very
highly metastatic human melanoma cell line (C8161) and a
prostate cancer cell line (PC3) in a CAM assay. We
investigated the progressive growth of tumours grafted onto
CAM ectoderm, and established a reproducible and simple
method to investigate capillary plexus (micro-vessels). We
have also investigated a high-resolution imaging method to
study intravasation in both wide diameter vessels
(macrovessels in the mesoderm) and the capillary plexus
(microvessels in the ectoderm) using this assay. 
Materials and Methods
Culturing melanoma and prostate cancer cell lines and primary
human fibroblasts. C8161 human cell line was isolated from an
abdominal wall metastasis from a recurrent malignant melanoma of
a menopausal woman (developed by Professor F. Meyskens UC
Irvine (USA) via Dr. M. Edwards (University of Glasgow, UK)).
C8161 human melanoma cells were grown in melanoma culture
medium consisted of EMEM media (Sigma-Aldrich, Dorset, UK)
supplemented with FCS (10% v/v), L-glutamine (2 μM), Pencillin
(100 U/ml), streptomycin (100 μg/ml) and Fungizone (0.625 μg/ml). 
The human prostate cancer cell line (PC-3) was a kind gift from
Dr. Adam Glen (initially purchased from the American Type Culture
Collection (Manassas, VA, USA)). PC-3 cells were cultured in T75
flasks and maintained in RPMI-1640 medium supplemented with
FCS (10% v/v), L-glutamine (2 μM), Penicillin (100 U/ml),
streptomycin (100 μg/ml) and Fungizone (0.625 μg/ml) (all from
Sigma-Aldrich, Dorset, UK). 
Human skin fibroblasts (HDF) were isolated from the dermal part
of split-thickness skin grafts as described previously (18, 19). After
isolation HDFs were expanded in DMEM medium (Sigma-Aldrich)
supplemented with FCS (10% v/v), L-glutamine (2 μM), penicillin
(100 U/ml), streptomycin (100 μg/ml) and Fungizone (0.625 μg/ml)
and used between passages 3 and 9. HDF isolation, storage and
experimentation was carried under a Local Ethics Committee
(Sheffield NHS Trust, Sheffield, UK) Approval and all tissue is
banked under a Human Research Tissue Bank License Human
Tissue Authority no 12179. All three cells types were initially grown
until 80% confluent in T75 flask before detaching, counting,
adjusting to required cell number and seeding. 
Studying angiogenesis
Incubation of eggs. Pathogen-free fertilized white leghorn chicken
eggs (Gallus gallus domesticus) were obtained from Henry Stewart
Co. Ltd (UK). Care was consistent with the guidelines of the Home
Office, UK. Chick embryos were cultured as described previously
(20). The egg shells were cracked and embryos were transferred into
a square Petri dish on embryonic development day (EDD) 3. The ex
ovo cultures were maintained in a humidified incubator at 38˚C
between EDDs 3 to 14. The survival of the embryos were checked
daily and recorded.
The ex ovo CAM assay. C8161, PC-3 and HDF cells were pre-
labelled with 1:1,000 concentration of Celltracker green™
(Invitrogen) and implanted on the CAM at embryonic
development day (EDD) 7, at an initial seeding density of 1×105.
Firstly, a plastic ring obtained by cutting a 2 mm thick slice of a
30G needle cover was placed on the CAM (Figure 1A). Then a
microtrauma was applied on the CAM by gently touching with the
bulb of a sterile Pasteur pipette. All chick embryos were then
randomly allocated to either HDF, C8161 and PC- 3 groups (5
chick embryos in each group per experiment for 3 independent
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experiments). One million HDF, C8161 or PC3 cells suspended in
30 μl of PBS were pipetted onto the CAM circumscribed with
plastic ring at EDD 7. At EDD 10, 12 and 14, primary area and
surrounding CAM images were taken by a digital microscope. For
fluorescent angiography 50 μl of a 5 μg/ml of rhodamine labelled
lens culinaris agglutinin (LCA) (Vector laboratories) was injected
in peripheral veins of the viable CAM using a 30G hypodermic
needle attached to a 1 ml syringe. After injection the needle was
withdrawn, haemostasis was established using a cotton swab and
the embryos were incubated for another 3 minutes to let the LCA
circulate. Embryos were then sacrificed by cutting the vitelline
arteries. CAM areas labelled with plastic rings were cut with a 1
cm margin around them and fixed in 3.7% paraformaldehyde
(Sigma Aldrich, Dorset, UK) in PBS.
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Figure 1. Schematic demonstration of running a CAM assay and the methodology used to image the macro and microvessels on the chorioallantoic
membrane (CAM) of the chick embryo. (A) Flow of events from embryonic development day (EDD) 0 to EDD 14 during ex ovo culture of chick
embryos. Incubation of fertilized eggs was started at EDD 0 and embryos were transferred into plastic weighing boats by cracking egg shells at
EDD 3. Fluorescent labelled cells were implanted onto the CAM using a plastic ring at EDD 7. Experimental outcomes were evaluated at EDDs
10, 12 and 14 where macrovessels were first imaged by a hand-held microscope. Then microinjection of a fluorescent tagged lectin was performed
and embryos were sacrificed. (B) Histological sectioning of the CAM reveals the cross-sectional view of the three-layered structure composed of
ectoderm, mesoderm and endoderm from top to bottom. The macrovessels are located in the mesoderm (arrow heads) and the microvessels (capillary
plexus) are located in the densely stained ectoderm. Confocal micrograph images of LCA- labelled endothelial cells of the vasculature shows both
macro (asterisk) and microvessels in different depths of focus.
The above method of seeding was compared in another
experiment, where 1 million C8161 cells were seeded on
electrospun poly(lactic acid) (PLA) scaffolds or encapsulated in a
gelatin based UV crosslinked hydrogel (21) for 24 hours and
implanted on CAM (EDD 7).
Quantification of angiogenesis
Macrovessels. HDFs, C8161 and PC-3 tumour cells were cultured on
the CAM until EDD 14. Digital images of the area of implantation
were taken at EDD 10, 12 and 14 using a digital microscope.
Quantification of angiogenesis was performed on 6 digital images
from each group following the processing methodology described
previously (22). Briefly, images were converted to grayscale, adaptive
thresholding was performed, noise removed and the percentage of
area covered by blood vessels was calculated. 
Microvessels. The microvasculature was imaged by confocal
microscopy after focusing on the capillary plexus located just above
the larger blood vessels on the top view of the fixed CAM tissues
(Figure 1B). Quantification of endothelial cell hypertrophy in
relation to implantation of tumour cells or HDFs in the adjacent
CAM tissues was studied on processed images constructed using
Image J software. Original images were converted to grayscale,
‘enhance contrast’ applied, bandpass filter applied and images were
‘thresholded’ to be most representative of original images. The total
area covered by endothelial cells in a frame was calculated. The
frames were taken from randomly selected areas of the CAM
adjacent to HDF or tumour cells. 
Studying tumour invasion
Confocal imaging. Fixed CAM samples were imaged at 3 time points
(10, 12 and 14 days) to track the growth of tumour cells implanted on
CAM ectoderm and intravasation of tumour cells in endothelial cells
by confocal microscopy. A Zeiss LSM 510 META confocal upright
microscope with Zeiss LSM Image Browser software (version
4.2.0121) was used to analyze the data. EC-plan Neofluar 5X and 10X
objective lenses was used (Celltracker green was excited at 488 nm
and emitted at BP500-550 nm, while rhodamine LCA was excited at
543 nm and emitted at BP565-615 nm). In depth analysis of tumour
implanted on the CAM optical images were taken at every 25 μm
interval, confocal settings (frame size 512×512, scan direction (single),
scan speed (4), data depth (8 bit), pinhole (1 Airy unit), laser power
and detector gain were all kept constant for all samples. Tumour
engraftment was defined as presence and proliferation of cells on
CAM at EDD 10, 12 and 14. Presence of cells was demonstrated by
confocal imaging of green fluorescent labelled cells on CAM
vasculature stained with LCA (CAM vessels through the sample,
Figure 1C). Proliferation was determined by an increase in mass of
cells at EDD 10, 12 and 14. Tumour invasion and intravasion was also
noticed consistently when the full depth of samples was imaged using
confocal z-stack settings.
Histology. Tissues were fixed in 3.7% paraformaldehyde (Sigma
Aldrich, USA) in PBS for at least 1 h. Histology was performed on
the retrieved samples. They were placed into molds for cryo-
sectioning filled with OCT solution (Leica, Germany). Samples
were left to freeze at –80˚C and 10 μm sections were cut with a
cryostat (Leica CM1860UV, Leica Germany). Slides were then
stained with haematoxylin & eosin (H&E), according to the
standard protocol for frozen slides. Slides were then covered with
DPX mountant (Sigma-Aldrich, Dorset, UK), covered with a glass
coverslip and imaged using a light microscope (Motic, China).
Tumour invasion was defined as presence of cells in the mesoderm
of the CAM as demonstrated by light and fluorescence microscopy
imaging of histologic sections (Figure 2). 
Statistical analysis. Statistical analysis was performed with SPSS v.
17.0. Differences between group means were analysed by Student’s
unpaired T-test when the data was normally distributed.
Comparisons of more than 2 groups was performed with one-way
ANOVA to determine the statistical significance. A p-value of <0.05
was considered statistically significant. 
Results
Evaluation of effect of engrafted HDFs or tumour cells on
macrovessels of the CAM. A progressive increase in blood
vessels formation was noticed in all micrographic images.
Visual inspection of images demonstrated an increase in
blood vessel formation at EDD 14 versus EDD 10 in all cell
lines (Figure 3A). It was also observed that there was a
normal increase in formation of blood vessels in the
developing embryo from EDD 10 to 14, though an enhanced
angiogenesis was noticed in the tumour group compared to
HDF group. The percentage areas covered by blood vessels
at days 10, 12 and 14 in HDF, C8161 and PC3 groups are
given in Table I. In all groups the total area covered by blood
vessels increased from EDD 10 to EDD 14 however the
response to C8161 and PC3 cells was statistically greater
than that to HDFs. There was no difference between groups
by EDD 10 but there was a significant difference between
HDF and HDF and PC3 groups on EDD 12 and between
C8161 and PC-3 cells and HDFs by EDD 14 (Figure 3). 
Implantation of tumour cells on CAM using tissue scaffolds.
When tumour cells (C8161) were seeded on polylactic acid
(PLA) scaffolds and implanted on the CAM, a visible
bleeding area inside the scaffold-tumour complex could be
observed in 9 out of 18 implanted samples (50%) as
compared to no bleeding in the 12 of the control PLA
scaffolds (Figure 3C). When tumour cells were encapsulated
in vivo 32: 461-472 (2018)
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Table I. Percentage area covered by blood vessels (quantification of
processed images in Figure 3B).
                      Day 10                        Day 12                          Day 14
                    % (±SD)                      % (±SD)                       % (±SD)
HDF         16.02 (±4,95)              20.21 (±5,27)              25,30 (±5,69)+
C8161      18.02 (±5.21)             26.28 (±6.39)+            35.52 (±7.07)*,+
PC3          18.23 (±4.29)            34.17 (±6.63)*,+         38.50 (±7.67)**,+
*p<0.05 compared to HDF on the same day. **p<0.005 compared to
HDF on the same day. +p<0.05 compared to day 10 on the same group.
n=5 for each time point in each group.
in the hydrogel before implantation on the CAM, no visible
bleeding could be observed in all of the 14 samples, most
probably due to poor tissue integration of the hydrogel and
the CAM. Instead the hydrogel carrier system appeared to be
good at demonstrating the tortuosity of the blood vessels
adjacent to hydrogel-tumour complex. After these initial
experiments we decided to implant the tumour cells directly
on CAM without using a cell carrier, as different matrices
demonstrated different responses in tumour vasculature. 
Evaluation of primary tumour implantation site on CAM.
The HDFs and tumour cells on the primary inoculation site
demonstrated progressive proliferation at EDD 10, 12 and
14. Tumour / HDF cells were pre-labelled with cell tracker
green while the endothelial cells were labelled with LCA. A
progressive growth of all 3-cell types was observed.
Interestingly, C8161 melanoma cell lines were found in a
large cellular mass compared to HDF and PC3 prostate cells
(Figure 4A, B). Individual tumour cells that detached from
the primary tumour mass could also be observed
intravasating from the lacuna to the cellular space (Figure
4C). Occasionally tumour thrombi could be detected inside
relatively larger vessels (Figure 4C). 
Demonstration of tumour invasion. Histologic sections of
the primary site by inoculation demonstrated that all 3-cell
types grew and formed cell masses or colonies on the
ectoderm surface of the CAM by EDD 14. It was observed
that HDFs formed a cellular uniform layer on top of the
ectoderm that could be clearly differentiated (Figure 5A).
The two distinct layers (HDF cell layer and ectoderm of
CAM) confirmed non-invasiveness of HDF cells. It was
also likely that the HDF uniform cellular layer was due to
the formation of extracellular matrix produced at EDD 14
(Figure 5A). In contrast, C8161 and PC-3 cells formed cell
mass/clumps unlike the HDF uniform ECM layer. The
tumour cell mass appeared to have invaded the CAM
ectoderm and even extended into the mesoderm (Figure
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Figure 2. Methodology used to demonstrate tumour invasion by histological sectioning (haematoxylin and eosin (H&E) and fluorescent labelled
images). Upper row: Human dermal fibroblasts (HDFs) are seen on top of the ectoderm together with the extracellular matrix (ECM) (arrow heads)
they have produced. The ectoderm of the CAM (red arrows) can clearly be followed underneath the HDF and ECM layer demonstrating non-
invasion. Corresponding fluorescent micrographs confirm the presence of green fluorescent labelled HDFs on top of the ectoderm (red arrows),
with no presence of HDFs in the mesoderm. Lower row: Human melanoma cells (C8161) can be seen as an aggregate (arrow head) on top of CAM
extending from the surface to the mesoderm in H&E sections. The ectoderm-mesoderm border (red arrows) is destructed (black arrows).
Corresponding fluorescent images confirm presence of fluorescently labelled tumour cells in the mesoderm of the CAM (green labelling/white arrow
head) with disruption of the ectoderm-mesoderm border (red arrows) confirming invasion (see inset).
in vivo 32: 461-472 (2018)
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Figure 3. The gross appearance of tumour-induced angiogenesis on the area of implantation of the tumour cells/ fibroblasts on the chick
chorioallantoic membrane (CAM). A) Micrographs of CAM regions at embryonic development days 10, 12 and 14 where human dermal fibroblasts
(HDF) (upper row), melanoma (C8161) cells (middle row) and prostate cancer cells (PC-3) (lower row) were implanted. B) Processed images for
each group at day 14 (quantification given in Table I). C) The quantification of images at B, the percentage area covered by blood vessels in each
group at day 14. Scale bars represent 2 mm. C) The tortuosity of tumour blood vessels can be observed when tumour cells are encapsulated in a
transparent hydrogel and implanted on CAM for 7 days. The fragility of blood vessels can be demonstrated as spontaneous bleeding (with movements
of the chick embryo) when tumour cells seeded on an electrospun PLA scaffold were cultured on CAM for 14 days.
5A, B). Histology sections of CAM samples labelled with
LCA for endothelial cells and cell tracker green for tumour
cells were imaged by fluorescent microscopy (Figure 5B).
The results showed similar clumps of cancer cells (C8161
and PC3) and a hypertrophied ectoderm. Furthermore,
cellular invasion of tumour cells into ectoderm and
mesoderm was also evident but it was not evident in HDF
samples (Figure 5B). Both tumour cell lines (C8161 and
PC3) demonstrated a consistent invasion in all samples,
though the distance of invasion in ectoderm or mesoderm
on EDDs 10, 12 and 14. 
Tumour invasion was also studied using confocal z-stack
imaging. X-Y axis images were taken through the z-axis of
samples every 25um (optical slice). The z-stack image was
then compressed to obtain an X-Y projection (Figure 6,
left), each emission depth was obtained using Depthcod
(Ziess LSM Image Browser). Each image stack required
images, including both microvessels (ectoderm) and
macrovessels (mesoderm). This is because the method
required optical sections to demarcate the two areas and it
was difficult to clearly demarcate ectoderm and mesoderm
when a large blood was not present at the same vertical
position with the tumour. Our results suggest some areas of
tumour mass (Figure 6 middle (green channel emission))
were at same depth as the macrovessels (Figure 6 right
(green channel emission)), demonstrating the presence of
tumour cells in the same plane as a large blood vessel of the
mesoderm (Figure 6). This was evident for tumours, but not
in case of HDF. 
Evaluation of microvessels on the primary site of cell
implantation. Figure 7A demonstrates the response of CAM
microvasculature to known proangiogenic (VEGF) and anti-
angiogenic (sunitinib) drugs. Endothelial cell hypertrophy
together with smaller lacunae can be observed in response to
VEGF whereas endothelial cell coverage was significantly
less with sunitinib treatment, which can be quantified (Figure
7B). A similar hypertrophy in the endothelial cells was
observed in the microvasculature adjacent to C8161 and PC3
cells in contrast to HDF (Figure 7C). 
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Figure 4. Confocal microscopic imaging of tumour-induced angiogenesis on the area of implantation of the cells on the chick chorioallantoic
membrane (CAM). (A) Implanted human dermal fibroblasts (HDF), melanoma cell line (C8161) and prostate cancer cell line (PC-3) can be tracked
on days 10, 12 and 14 and the increase in tumour volume can be demonstrated to increase at the primary site of implantation over days. Scale bars
represent 100 μm. (B) Total increase in the main cell mass was most prominent in C8161, PC3 and HDF respectively. (C) In closer view, individual
cells that detaching from the main tumour mass could be detected intravasating into the endothelial cells in the adjacent areas. (D) Another tumour
characteristic, tumour thrombi, can also be observed in the lager blood vessels. HDF, C8161 and PC3 cells are labelled with cell tracker green,
endothelial cells are labelled with rhodamine conjugated lens culinaris agglutinin.
Discussion
Accessible models to study tumour angiogenesis that are able
to represent the complexity of 3D living systems are needed
to study the mechanisms of tumour biology and progression
as well as testing newly developed drugs. This study reports
on an in vivo bioassay methodology based on the chick
chorioallantoic membrane (CAM) that can be used for both
qualitative and quantitative assessment of tumour angiogenesis
at both macro and microscopic levels. We present a
significant improvement on the classical assay by
systematically combining several techniques to study some
important aspects of tumour angiogenesis. We demonstrate
that optical sectioning can be used in conjunction with
histology sectioning to study tumour invasion, and that tissue
engineered tumour constructs can be used to study the
functional abnormality (fragile/leaky) of tumour vessels in an
in vivo system. 
in vivo 32: 461-472 (2018)
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Figure 5. Evaluation of tumour invasion at the primary tumour site by histologic sectioning and fluorescent staining. A) H&E images demonstrate
that fibroblasts (HDF) grow on the surface without invading through the ectoderm of the CAM (dashed arrows) and a significant amount of ECM
(arrow heads) can be observed on the CAM at day 14. With the melanoma (C8161) and prostate cancer (PC3) cell lines, tumour clumps can be
seen on the surface of the CAM (arrow heads) and they damage the ectoderm extending through to the mesoderm (dashed arrows). B) Fluorescent
staining demonstrates that green fluorescent labelled C8161 and PC3 cells invade through the ectoderm of the CAM. Invasion is defined as presence
of tumour cells in mesoderm of the CAM.
We report that all cells when placed on a highly vascularized
chorioallantoic membrane of fertilised chick eggs grew over
time. This approach provides a good alternative to the use of
small animals, and offers an economical and fast experimental
alternative to study tumour angiogenesis and invasion.
Furthermore, we have demonstrated that 3D optical imaging of
the CAM tissue can illustrate tumour growth and the tumour
influence on angiogenesis. The CAM assay is a well-established
assay that has long been used as an in vivo environment to study
tumour metastasis and angiogenesis (23). Both in ovo (24) and
ex ovo (shell less) (25) techniques have been used in previous
studies to culture chick embryos. Although there is no major
difference conceptually between the two methods (26), we
selected the ex ovo technique as it allows better visualization of
the blood vessels especially when studying angiogenesis and
intravasation and it facilitates injections into the circulation. The
main disadvantage of this technique is reported decreased
embryo survival rates (27, 28). The survival rate in our hands
for the ex ovo technique was above 70% (29). 
We then demonstrated that the change in the overall
appearance of the larger blood vessels can be quantified
when tumour cells are implanted on a circumscribed area of
CAM. While we explored several different methods of
introducing melanoma cells onto the CAM (e.g. by placing
cells within a hydrogel, or culturing them on a tissue
engineered PLA scaffold), we found that the simplest
approach was to use a simple cell suspension dropped within
a light plastic ring placed on the CAM. 
We used a published image analysis methodology to quantify
the change in macrovessels (22). This methodology was
applicable because we did not use a cell carrier material unlike
previous studies that have used Matrigel or a collagen matrix to
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Figure 6. Demonstration of tumour invasion by optical sectioning in confocal microscopy. Projected Z stack images of all sections demonstrate
HDF, C8161 and PC3 cells in relation to blood vessels of the CAM. Channel (green) locates the HDFs or tumour cells on the surface of and
extending to the mesoderm of the CAM. Channel (red) locates the presence of blood vessels in the whole thickness of the imaged CAM. The depth
map of the green and red channels taken together demonstrates extension of the tumour cells to the level of bigger blood vessels in the mesoderm
confirming invasion. Scale bars represent 200 μm.
implant tumour cells on the CAM (17). Although using a cell
carrier has obvious advantage of keeping tumour cells together,
our initial experiments demonstrated a moderate inflammatory
reaction to the natural ECM based carriers especially after EDD
12 (30). Inflammation is known to stimulate angiogenesis,
which could also affect the quality of imaging. 
The CAM, being a naturally immunodeficient host, is
known to accept grafted tissues and cells (31-33). Furthermore,
the CAM contains extracellular matrix proteins such as
laminin, fibronectin, type I collagen, integrins and MMP-2
making it a useful model to study tumour invasion (34).
Histological investigation in many studies have demonstrated
invasion of the CAM ectoderm by tumours of different origins
(28, 35). Here we present a demonstration of tumour invasion
by optical sectioning, in addition to traditional histologic and
fluorescent staining. By using confocal microscopy, we
demonstrated the presence of tumour cells in the mesoderm of
the CAM in cases where tumour inoculums were localized in
close proximity to large blood vessels. One limitation of this
technique was in the absence of adjacent large blood vessels
and when the mesoderm was not thick enough, then the layers
could not be differentiated by optical sectioning.
Following tumour growth, metastasis ensues by a cascade
of events; detachment from the primary tumour, invasion of
local stroma, entering the circulation (intravasation), surviving
in the circulation, exiting from the circulation (extravasation)
and engrafting in the metastatic site (36). With its accessible
capillary plexus the CAM offers a unique environment to study
tumour intravasation, dissemination and vascular arrest.
Individual tumour cells that detach from the main mass
intravasate to start the metastatic cascade. Tumour intravasation
has also been studied in tumour masses formed in rats,
however the visual data produced is rather unsatisfactory (37,
38) despite the specialized imaging techniques used. 
In contrast to physiological angiogenesis, tumour related
angiogenesis is characterized by structurally and functionally
abnormal, disorganized, fragile and leaky vessels (39-41). An
excessive production of VEGF together with a loss of balance
between the pro and anti- angiogenic factors present in the
tumour microenvironment mediates this process. We could
demonstrate the tortuous blood vessels forming in relation to
tumour cells by using a hydrogel as a cell carrier. This hydrogel
is composed of cross linked gelatin (21) which makes it less
antigenic and it does not integrate into CAM tissues allowing
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Figure 7. Demonstration of abnormal structure and function of tumour blood vessels. Evaluation of microcirculation adjacent to tumour cells. A)
Demonstration of how CAM microvasculature appears normally (control) and how it responds to pro-angiogenic (VEGF) and anti-angiogenic
(sunitinib) compounds. VEGF results in endothelial cell hypertrophy and smaller lacunea when applied to CAM surface whereas sunitinib results
in much larger lacunae and areas of CAM devoid of endothelial cell coverage (avascular areas). B) Quantification of area covered by endothelial
cells and the lacunea. C) In response to the presence of C8161 and PC3 cells, but not fibroblasts, local areas of endothelial cell hypertrophy can
be observed in areas adjacent to tumour cells.
us to study the paracrine action of tumour cells. A stiffer
extracellular matrix, electrospun PLA scaffold, was necessary
to demonstrate the spontaneous bleeding as the chick embryo
moved. To the best of our knowledge spontaneous bleeding
inside the 3D tumour construct has not been demonstrated
previously. One study demonstrated bleeding upon injection of
tumour cells in a dorsal skin chamber (42). 
A limitation of the current study is that only 2 established
human cell lines were used to establish the model rather than
excised human tumours. We chose human melanoma cells as
this can spread locally and via the bloodstream (43). Also, it is
known to be an angiogenic tumour type, whose aggressiveness
is related to its vascularization status (44, 45). Prostate cancer
cells were chosen as a solid tumour where antiangiogenic
therapies have not shown any benefit despite the fact that
angiogenesis plays a critical role in progression to metastatic
prostate cancer (46). Tumours from different origins can be
expected to induce different angiogenic responses. 
Now that this model is established the next step will be to
use it to study its angiogenic response to patient derived
xenografts. We suggest this will be possible as previous studies
have shown that solid tumours of different origins grown on
CAM repeatedly formed solid tumours within days and their
histologic appearances closely resembled the corresponding
tumours from clinical specimens (47). Especially aggressive
tumours for which treatments are largely ineffective (e.g.
cholangiocarcinoma), tumour invasiveness and anti- tumour
activity of new agents (e.g. metformin) can also be studied in
this model (48). Metformin has also been suggested as a
promising agent for metastatic prostate cancer when combined
with the docetaxel chemotherapy (49) which is the current
standard treatment (50). The challenge will be to see their
response to anti-angiogenic drugs.
Conclusion
We report on a CAM assay as an effective methodology to
study tumour-related changes in macro and micro blood
vessels while allowing progressive tumour growth and
invasion in an in vivo system. The main advantage of this
approach is the fact that it offers an accessible approach to
study tumour intravasation and we suggest that it will be
amenable to use with human tumour biopsies and to determine
the response of tumours to drugs in current clinical use. We
hope it will become a useful model for providing much more
information on the responsiveness of different tumours and of
tumours from different patients to anti-angiogenic therapies.
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